Search the Newsreel

HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma

HC Wainwright has revised its Q3 2026 EPS estimate for Nuvectis Pharma (NASDAQ:NVCT) to a loss of $0.23 per share, an improvement from its previous forecast of a $0.26 loss, while reiterating a "Buy" rating and a $39 price target. Nuvectis Pharma reported a …

Soleus group (NVCT) discloses 1.65M-share, 5.1% Nuvectis Pharma stake

Soleus group,

(NVCT) Movement Within Algorithmic Entry Frameworks

The article analyzes Nuvectis Pharma Inc. (NVCT) using algorithmic entry frameworks, highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It presents exceptional risk-reward short setup opportunities and outlines three distinct institutional trading strategies based on AI models, including …

Lucid Capital Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $34

Lucid Capital has reiterated its Buy rating on Nuvectis Pharma (NVCT.US) and increased its price target to $34. This update indicates a positive outlook from the investment firm regarding the pharmaceutical company's future performance.

Nuvectis Pharma (NASDAQ: NVCT) boosts cash with $115M stock sale and new drug licenses

Nuvectis Pharma (NASDAQ: NVCT) recently raised $115 million through a public stock offering, generating approximately $106.3 million in net proceeds. This capital, combined with existing cash, is expected to fund operations for at least 12 months. Additionally, the company secured global rights (excluding China …

Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings Miss

Nuvectis Pharma (NASDAQ:NVCT) shares gapped down following an earnings miss, with the company reporting a quarterly EPS of negative $0.30 against an estimated negative $0.25. Despite the miss, analyst sentiment is mixed, with some issuing "buy" ratings and higher price targets, while the consensus …

Nuvectis Pharma, Inc. 2Q 2026: Net loss $(7.02)M, EPS $(0.30) — 10-Q Summary

Nuvectis Pharma, Inc. reported a net loss of $(7.02)M and an EPS of $(0.30) for Q2 2026, with no revenue generated since inception. The company is advancing its clinical pipeline, including licensing global rights for NXP100 and NXP200, and increasing R&D spending. A recent …

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma, a clinical-stage biopharmaceutical company, reported its Q2 2026 financial results and significant business achievements, including the in-licensing of two new drug candidates, ciprocopan (NXP100) and NXP200. The company announced that ciprocopan received marketing approval in China for PNH treatment and successfully raised …

Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS

Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview

Nuvectis Pharma Inc (NVCT) is projected to report a loss of 26 cents per share, according to this earnings preview. The article, sourced from Reuters, provides an outlook on the company's financial performance.

Nuvectis Pharma Inc (NVCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Nuvectis Pharma Inc (NVCT), detailing support, resistance, indicators, and moving averages. It presents a summary of technical indicators with values and directions, noting a Neutral signal for overall technical analysis despite several buy signals from moving averages. …

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

Wall Street analysts predict a potential 56.41% upside for Nuvectis Pharma (NVCT), with a mean price target of $31 despite the stock's recent 7.8% gain. This optimism is further supported by positive revisions in earnings estimates, leading to a Zacks Rank #2 (Buy) for …

Nuvectis Pharma (NVCT) Expected to Announce Earnings on Tuesday

Nuvectis Pharma Inc (NVCT) Financial Health: Profitability & Balance Sheet Analysis

This article from TradingKey provides a financial health overview of Nuvectis Pharma Inc (NVCT). It indicates that the company has a market capitalization of $519.10 million and is currently trading at $19.570. The piece appears to be an introductory analysis, referencing profitability and balance …

Nuvectis Pharma Inc (NVCT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Nuvectis Pharma Inc (NVCT), detailing its stock performance and market capitalization. It highlights that key valuation metrics such as P/E, P/B, and P/CF ratios have not yet been disclosed by the company. The page also presents an …

Nuvectis Pharma Inc (NVCT) Income Statement

NVCT|Nuvectis Pharma Inc|Price:19.310|Chg%:-0.840

Nuvectis Pharma Inc (NVCT) is a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology, specifically two drug candidates: NXP800 and NXP900. NXP800 is in Phase 1b clinical trials for platinum-resistant, ARID1a-mutated ovarian carcinoma and cholangiocarcinoma, while NXP900 is undergoing a Phase 1a …

Nuvectis Pharma (NVCT) Short Interest & Short Float | Updated Jul 2026

As of July 15, 2026, Nuvectis Pharma (NVCT) reported a short interest of 1.51 million shares, representing 7.98% of its public float, marking a 16.12% decrease from the previous report. The short interest ratio is 4.0 days to cover, indicating it would take four …

H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $39

H.C. Wainwright has reiterated its Buy rating on Nuvectis Pharma (NVCT.US) and maintained a target price of $39. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Correction: Nuvectis Announces Marketing Approval of Ciprocopan in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Nuvectis Pharma, Inc. announced that its partner Haisco has received marketing approval in China for ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, to treat patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with complement inhibitors. This marks the world's first approval for …

Nuvectis Drug Reached 12 g/dL in 59.5% of PNH Patients

Nuvectis Pharma announced that its once-daily oral Complement Factor B inhibitor, ciprocopan (NXP100), has received marketing approval in China for treating Paroxysmal Nocturnal Hemoglobinuria (PNH) patients previously untreated with complement inhibitors. This marks the first global approval for such a drug and is based …

Ciprocopan (NXP100) Receives Marketing Approval in China

Nuvectis Pharma, Inc. announced that its drug ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, has received marketing approval in China for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) untrained with complement inhibitors. This approval marks the world's first for such a drug, providing …

Nuvectis Pharma Announces Major Public Equity Offering

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma, Inc. Actuals & Estimates (NASDAQ:NVCT)

What Makes Nuvectis Pharma (NVCT) a New Buy Stock

NVCT Forecast — Price Target — Prediction for 2027

NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Cost Discipline - Analyst Consensus Shift

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth

Nuvectis Pharma Inc. (NVCT) Stock Price | Live Quotes & Charts | NASDAQ

Should I buy Nuvectis Pharma (NVCT)

Nuvectis Pharma (NVCT) Stock Price, News & Analysis